-
NNESAM Supports Strengthening Legal Protections for Drug Checking Equipment in New Hampshire
Full story -
ASAM Announces New Board of Directors for 2025-2027 Term
Full story -
The ASAM Weekly for January 21st, 2025
Current Advances in Behavioral AddictionsFull story -
KYSAM Pushes Back Against Potential Reinstating of Prior Authorization on Medications for OUD
Full story -
ASAM Supports DEA and HHS Final Rule on Telemedicine Initiation of Buprenorphine Treatment for OUD
Full story -
The ASAM Weekly for January 14th, 2025
Review of Evidence on Alcohol and HealthFull story -
ASAM Applauds FDA Clarification for Buprenorphine Labeling
Full story -
The ASAM Weekly for January 7th, 2025
2024 ASAM Weekly Guest EditorialsFull story -
The ASAM Weekly for December 31st, 2024
ASAM Weekly Top 10 News Articles of 2024Full story -
The ASAM Weekly for December 24th, 2024
ASAM Weekly Top 10 Peer-Reviewed Scientific Publications of 2024Full story -
Congress Misses Crucial Opportunity to Include Lifesaving Addiction Treatment Legislation in Year-End Package; ASAM Calls for Immediate Action in 2025
Full story -
ASAM Joins Letter Calling to End $75 Contingency Management Restriction
Full story -
VASAM Comments on Proposed Buprenorphine Treatment Regulations
Full story -
The ASAM Weekly for December 17th, 2024
The impact of schizophrenia genetic load and heavy cannabis use on the risk of psychotic disorderFull story -
COSAM Supports Removing Restrictions on SSPs in Denver
Full story -
ASAM Encourages CMS to Strengthen Medicaid Parity Regulations
Full story -
ASAM Joins Letter Requesting Federal Best Practices to Protect Youth Amidst Marijuana Legalization in States
Full story -
The ASAM Weekly for December 3rd, 2024
Xylazine Pharmacokinetics in Patients Testing Positive for Fentanyl and XylazineFull story -
The ASAM Weekly for November 26th, 2024
Women, gender and drugsFull story -
ASAM Calls on Congress to Pass the Reentry Act and Due Process Continuity of Care Act
Full story